Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | EGFR | P00533 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 4/20 | 0.45 |
| ▸ | CA1 | P00915 | 4/20 | 0.45 |
| ▸ | CA2 | P00918 | 4/20 | 0.45 |
| ▸ | CA7 | P43166 | 4/20 | 0.45 |
| ▸ | CA9 | Q16790 | 4/20 | 0.45 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.40 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.40 |
| ▸ | CASP1 | P29466 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13061852 | 0.86 | TSHR (0.47) | TSHREGFRCA12CA1CA2 | |
| SCHEMBL28237983 | 0.83 | ALDH1A1 (0.50) | TSHRCA12CA1CA2CA7 | |
| SCHEMBL25838143 | 0.79 | CA12 (0.47) | TSHREGFRCA12CA1CA2 | |
| SCHEMBL7992543 | 0.78 | TSHR (0.69) | TSHRCA12CA1CA2CA7 | |
| SCHEMBL22162979 | 0.75 | CA12 (0.54) | TSHREGFRCA12CA1CA2 | |
| SCHEMBL11955135 | 0.74 | TSHR (0.44) | TSHRCA12CA1CA2CA7 | |
| SCHEMBL2609143 | 0.74 | CA12 (0.66) | TSHREGFRCA12CA1CA2 | |
| SCHEMBL1548153 | 0.74 | CA1 (0.63) | CA12CA1CA2CA7CA9 | |
| SCHEMBL19050355 | 0.73 | MEN1 (0.47) | TSHREGFRALDH1A1MAPTKDM4E | |
| SCHEMBL13375810 | 0.73 | KDM4E (0.47) | TSHREGFRCA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100322854-A1 | POSITRON EMISSION TOMOGRAPHY IMAGING METHOD | PURDUE RESEARCH FOUNDATION (US) | 2010-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100322854-A1 | POSITRON EMISSION TOMOGRAPHY IMAGING METHOD | VDR, FOLR2, SLC46A1 | TSHR 287/4885EGFR 433/4885CA12 1172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.